Personalized primary tumor xenograft model established for the pre-clinical trial to guide postoperative chemotherapy

Medical Hypotheses

Volumn 79, Issue 6, 2012, Pages 705-708

  Han, Chenglong ^a   Shen, Jie ^a   Wang, Hao ^a   Yu, Lixia ^a   Qian, Xiaoping ^a   Liu, Baorui ^a   Guan, Wenxian ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; PEMETREXED;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER TRANSPLANTATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; ORGAN TRANSPLANTATION; POSTOPERATIVE CARE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STOMACH CANCER; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MICE; MICE, NUDE; MODELS, THEORETICAL; NEOPLASMS; PILOT PROJECTS; POSTOPERATIVE CARE; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84869087346     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.06.009     Document Type: Article

References (33)

1. Gonzalez-Angulo A.M., Hennessy B.T., Mills G.B. Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol 2010, 28(16):2777-2783.
2. Schilsky R.L. Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 2010, 9(5):363-366.
3. Chin L., Andersen J.N., Futreal P.A. Cancer genomics: from discovery science to personalized medicine. Nat Med 2011, 17(3):297-303.
4. Scholz C.C., Berger D.P., Winterhalter B.R., Henss H., Fiebig H.H. Correlation of drug response in patients and in the clonogenic assay with solid human tumour xenografts. Eur J Cancer 1990, 26(8):901-905.
5. Ohyama S., Yonemura Y., et al. Chemosensitivity test for gastric cancer by in vitro MTT assay. Gan To Kagaku Ryoho 1991, 18(10):1593-1597.
6. Knight L.A., Conroy M., Fernando A., Polak M., Kurbacher C.M., Cree I.A. Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay. Anticancer Drugs 2005, 16(9):969-976.
7. Higashiyama M., Oda K., Okami J., et al. In vitro-chemosensitivity test using the collagen gel droplet embedded culture drug test (CD-DST) for malignant pleural mesothelioma: possibility of clinical application. Ann Thorac Cardiovasc Surg 2008, 14(6):355-362.
8. Pathak K.A., Juvekar A.S., Radhakrishnan D.K., et al. In vitro chemosensitivity profile of oral squamous cell cancer and its correlation with clinical response to chemotherapy. Indian J Cancer 2007, 44(4):142-146.
9. Debes A., Rommel F., Breise M., Willers R., Gobel U., Wessalowski R. In vitro test-system for chemo- and thermosensitivity: an analysis of survival fractions and cell-cycle distributions in human Ewing's sarcomas as a model for tumors in pediatric oncology. Klin Padiatr 2002, 214(4):223-229.
10. Talmadge J.E., Singh R.K., Fidler I.J., Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 2007, 170(3):793-804.
11. Sausville E.A., Burger A.M. Contributions of human tumor xenografts to anticancer drug development. Cancer Res 2006, 66:3351-3354.
12. Villarroel M.C., Rajeshkumar N.V., Garrido-Laguna I., et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther 2011, 10(1):3-8.
13. Hidalgo M., Bruckheimer E., Rajeshkumar N.V., et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011, 10(8):1311-1316.
14. Fichtner I., Rolff J., Soong R., et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 2008, 14(20):6456-6468.
15. Marangoni E., Vincent-Salomon A., Auger N., et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007, 13(13):3989-3998.
16. Moskaluk C.A., Baras A.S., Mancuso S.A., et al. Development and characterization of xenograft model systems for adenoid cystic carcinoma. Lab Invest 2011, 91(10):1480-1490.
17. John T., Kohler D., Pintilie M., et al. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. Clin Cancer Res 2011, 17(1):134-141.
18. Garrido-Laguna I., Uson M., Rajeshkumar N.V., et al. Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res 2011, 17(17):5793-5800.
19. Dong X., Guan J., English J.C., et al. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin Cancer Res 2010, 16(5):1442-1451.
20. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
21. Mbeunkui F., Johann D.J. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol 2009, 63(4):571-582.
22. Nagy J.A., Chang S.H., Shih S.C., et al. Heterogeneity of the tumor vasculature. Semin Thromb Hemost 2010, 36(3):321-331.
23. Baluk P., Hashizume H., McDonald D.M. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005, 15(1):102-111.
24. Weber C.E., Kuo P.C. The tumor microenvironment. Surg Oncol 2011.
25. De Wever O., Nguyen Q.D., Van Hoorde L., et al. Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J 2004, 18(9):1016-1018.
26. Orimo A., Gupta P.B., Sgroi D.C., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121(3):335-348.
27. Singer C.F., Kronsteiner N., Marton E., et al. MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions. Breast Cancer Res Treat 2002, 72(1):69-77.
28. DeNardo D.G., Andreu P., Coussens L.M. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev 2010, 29(2):309-316.
29. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 40(6):883-899.
30. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141(1):39-51.
31. Karnoub A.E., Dash A.B., Vo A.P., et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449(7162):557-563.
32. Derose Y.S., Wang G., Lin Y.C., et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011, 17(11):1514-1520.
33. Workman P., Aboagye E.O., Balkwill F., et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010, 102(11):1555-1577.